IDH1 and central nervous system cancer: Among targeted therapies, vorasidenib, an IDH1/2 mutation inhibitor, was recently shown to improve PFS and delay the time to next intervention, relative to placebo in patients with IDH-mutant grade 2 glioma, which may suggest considerable potential to widen the therapeutic options for IDH-mutant low-grade glioma (122).